COVID-19

[Science Advances] Scientists used the high-density microarray patch to deliver a SARS-CoV-2 spike subunit vaccine directly to the skin.

[Lancet Global Health] The authors assessed the efficacy of fluvoxamine versus placebo in preventing hospitalisation defined as either retention in a COVID-19 emergency setting or transfer to a tertiary hospital due to COVID-19.

[Nature Communications] Scientists examined potential confounders in COVID-19 respiratory microbiome studies by analyzing the upper and lower respiratory tract microbiome in well-phenotyped COVID-19 patients and controls combining microbiome sequencing, viral load determination, and immunoprofiling.

[Journal of Clinical Investigation] The authors highlight the current understanding, evolving concepts, and unanswered questions provided by this unique opportunity to determine mechanisms by which a viral infection can be exacerbated by, and even trigger, autoimmunity.

[TFF Pharmaceuticals, Inc.] TFF Pharmaceuticals, Inc. announced that it has received approval from Health Canada to begin a Phase I clinical trial of a dry powder formulation of niclosamide, an antiviral treatment with potential to address COVID-19 and other infectious diseases.

[Translational Research] There is little known about risk factors or predictors of susceptibility for Long-Hauler's Syndrome, but older adults are at greater risk for severe outcomes and mortality from COVID-19.